5 July 2023
ECO Animal Health Group plc
(''ECO", the "Company" or the "ECO Group")
(AIM: EAH)
Notice of Results & Investor Presentation
ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, will issue its results for the year ended 31 March 2023 on Monday 10 July 2023.
Investor Presentation
David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the company's FY Results for the period ended 31 March 2023. The online presentation will take place on Wednesday 12 July at 2.30pm UK time.
This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it. Please register using the following link:
https://www.equitydevelopment.co.uk/news-and-events/ecoanimalhealth-fyresultspresentation-12july2023
For further information please contact:
| ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
| 020 8447 8899
|
|
IFC Advisory Graham Herring Zach Cohen
|
020 3934 6630
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies George Tzimas |
020 7496 3000 |
|
Investec (Joint Broker) Gary Clarence Lydia Zychowska Carlo Spingardi |
020 7597 5970
|
| Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
